{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:15:27Z","timestamp":1788394527950,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by the Department of Pediatrics and The Sarah M. & Charles E. Seay Chair in Pediatric Infectious Diseases, The University of Texas Southwestern Medical Center, Dallas, Texas."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic interventions targeting viral infections remain a significant challenge for both the medical and scientific communities. While specific antiviral agents have shown success as therapeutics, viral resistance inevitably develops, making many of these approaches ineffective. This inescapable obstacle warrants alternative approaches, such as the targeting of host cellular factors. Respiratory syncytial virus (RSV), the major respiratory pathogen of infants and children worldwide, causes respiratory tract infection ranging from mild upper respiratory tract symptoms to severe life-threatening lower respiratory tract disease. Despite the fact that the molecular biology of the virus, which was originally discovered in 1956, is well described, there is no vaccine or effective antiviral treatment against RSV infection. Here, we demonstrate that targeting host factors, specifically, mTOR signaling, reduces RSV protein production and generation of infectious progeny virus. Further, we show that this approach can be generalizable as inhibition of mTOR kinases reduces coronavirus gene expression, mRNA transcription and protein production. Overall, defining virus replication-dependent host functions may be an effective means to combat viral infections, particularly in the absence of antiviral drugs.<\/jats:p>","DOI":"10.1038\/s41598-021-03814-7","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T06:02:55Z","timestamp":1640325775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["mTOR kinase is a therapeutic target for respiratory syncytial virus and coronaviruses"],"prefix":"10.1038","volume":"11","author":[{"given":"HoangDinh","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Levitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"3814_CR1","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1056\/NEJM200106213442507","volume":"344","author":"CB Hall","year":"2001","unstructured":"Hall, C. B. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344, 1917\u20131928. https:\/\/doi.org\/10.1056\/NEJM200106213442507 (2001).","journal-title":"N. Engl. J. Med."},{"key":"3814_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/s0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375, 1545\u20131555. https:\/\/doi.org\/10.1016\/s0140-6736(10)60206-1 (2010).","journal-title":"Lancet"},{"key":"3814_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/infdis\/151.4.626","volume":"151","author":"LJ Anderson","year":"1985","unstructured":"Anderson, L. J. et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J. Infect. Dis. 151, 626\u2013633 (1985).","journal-title":"J. Infect. Dis."},{"key":"3814_CR4","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1086\/315508","volume":"181","author":"TC Peret","year":"2000","unstructured":"Peret, T. C. et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J. Infect. Dis. 181, 1891\u20131896 (2000).","journal-title":"J. Infect. Dis."},{"key":"3814_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1073\/pnas.93.1.81","volume":"93","author":"PL Collins","year":"1996","unstructured":"Collins, P. L., Hill, M. G., Cristina, J. & Grosfeld, H. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc. Natl. Acad. Sci. U. S. A. 93, 81\u201385. https:\/\/doi.org\/10.1073\/pnas.93.1.81 (1996).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"3814_CR6","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1128\/JVI.70.9.6143-6150.1996","volume":"70","author":"L Kuo","year":"1996","unstructured":"Kuo, L., Fearns, R. & Collins, P. L. The structurally diverse intergenic regions of respiratory syncytial virus do not modulate sequential transcription by a dicistronic minigenome. J. Virol. 70, 6143\u20136150. https:\/\/doi.org\/10.1128\/JVI.70.9.6143-6150.1996 (1996).","journal-title":"J. Virol."},{"key":"3814_CR7","doi-asserted-by":"publisher","first-page":"11563","DOI":"10.1073\/pnas.92.25.11563","volume":"92","author":"PL Collins","year":"1995","unstructured":"Collins, P. L. et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5\u2032 proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. U. S. A. 92, 11563\u201311567. https:\/\/doi.org\/10.1073\/pnas.92.25.11563 (1995).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"3814_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1006\/viro.1998.9535","volume":"254","author":"JS Kahn","year":"1999","unstructured":"Kahn, J. S., Schnell, M. J., Buonocore, L. & Rose, J. K. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254, 81\u201391. https:\/\/doi.org\/10.1006\/viro.1998.9535 (1999).","journal-title":"Virology"},{"key":"3814_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0042-6822(62)90293-3","volume":"16","author":"AL Kisch","year":"1962","unstructured":"Kisch, A. L., Johnson, K. M. & Chanock, R. M. Immunofluorescence with respiratory syncytial virus. Virology 16, 177\u2013189. https:\/\/doi.org\/10.1016\/0042-6822(62)90293-3 (1962).","journal-title":"Virology"},{"key":"3814_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1099\/0022-1317-26-2-183","volume":"26","author":"EA Follett","year":"1975","unstructured":"Follett, E. A., Pringle, C. R. & Pennington, T. H. Virus development in enucleate cells: Echovirus, poliovirus, pseudorabies virus, reovirus, respiratory syncytial virus and Semliki Forest virus. J. Gen. Virol. 26, 183\u2013196. https:\/\/doi.org\/10.1099\/0022-1317-26-2-183 (1975).","journal-title":"J. Gen. Virol."},{"key":"3814_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/oxfordjournals.aje.a119902","volume":"66","author":"R Chanock","year":"1957","unstructured":"Chanock, R. & Finberg, L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am. J. Hyg. 66, 291\u2013300. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a119902 (1957).","journal-title":"Am. J. Hyg."},{"key":"3814_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3181\/00379727-92-22538","volume":"92","author":"RE Blount Jr","year":"1956","unstructured":"Blount, R. E. Jr., Morris, J. A. & Savage, R. E. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. 92, 544\u2013549. https:\/\/doi.org\/10.3181\/00379727-92-22538 (1956).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"3814_CR13","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1542\/peds.2006-2223","volume":"118","author":"AS Lieberthal","year":"2006","unstructured":"Lieberthal, A. S. et al. Diagnosis and management of bronchiolitis. Pediatrics 118, 1774\u20131793. https:\/\/doi.org\/10.1542\/peds.2006-2223 (2006).","journal-title":"Pediatrics"},{"key":"3814_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1542\/peds.102.5.1211","volume":"102","author":"NA Halsey","year":"1998","unstructured":"Halsey, N. A. et al. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102, 1211\u20131216 (1998).","journal-title":"Pediatrics"},{"key":"3814_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2016.08.006","volume":"134","author":"R Fearns","year":"2016","unstructured":"Fearns, R. & Deval, J. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase. Antiviral Res. 134, 63\u201376. https:\/\/doi.org\/10.1016\/j.antiviral.2016.08.006 (2016).","journal-title":"Antiviral Res."},{"key":"3814_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00431-018-03310-7","volume":"178","author":"Y Xing","year":"2019","unstructured":"Xing, Y. & Proesmans, M. New therapies for acute RSV infections: Where are we?. Eur. J. Pediatr. 178, 131\u2013138. https:\/\/doi.org\/10.1007\/s00431-018-03310-7 (2019).","journal-title":"Eur. J. Pediatr."},{"key":"3814_CR17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3201\/eid2006.131438","volume":"20","author":"CN Agoti","year":"2014","unstructured":"Agoti, C. N., Otieno, J. R., Gitahi, C. W., Cane, P. A. & Nokes, D. J. Rapid spread and diversification of respiratory syncytial virus genotype ON1, Kenya. Emerg. Infect. Dis. 20, 950\u2013959. https:\/\/doi.org\/10.3201\/eid2006.131438 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"3814_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/CMR.00010-16","volume":"30","author":"C Griffiths","year":"2017","unstructured":"Griffiths, C., Drews, S. J. & Marchant, D. J. Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment. Clin. Microbiol. Rev. 30, 277\u2013319. https:\/\/doi.org\/10.1128\/CMR.00010-16 (2017).","journal-title":"Clin. Microbiol. Rev."},{"key":"3814_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 169, 361\u2013371. https:\/\/doi.org\/10.1016\/j.cell.2017.03.035 (2017).","journal-title":"Cell"},{"key":"3814_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1743-422X-9-190","volume":"9","author":"R Levitz","year":"2012","unstructured":"Levitz, R. et al. Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific. Virol. J. 9, 190. https:\/\/doi.org\/10.1186\/1743-422X-9-190 (2012).","journal-title":"Virol. J."},{"key":"3814_CR21","doi-asserted-by":"publisher","first-page":"e0184318","DOI":"10.1371\/journal.pone.0184318","volume":"12","author":"R Levitz","year":"2017","unstructured":"Levitz, R. et al. Distinct patterns of innate immune activation by clinical isolates of respiratory syncytial virus. PLoS ONE 12, e0184318. https:\/\/doi.org\/10.1371\/journal.pone.0184318 (2017).","journal-title":"PLoS ONE"},{"key":"3814_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1086\/342414","volume":"186","author":"RA Martinello","year":"2002","unstructured":"Martinello, R. A., Chen, M. D., Weibel, C. & Kahn, J. S. Correlation between respiratory syncytial virus genotype and severity of illness. J. Infect. Dis. 186, 839\u2013842. https:\/\/doi.org\/10.1086\/342414 (2002).","journal-title":"J. Infect. Dis."},{"key":"3814_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181\u2013192. https:\/\/doi.org\/10.1038\/s41579-018-0118-9 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"3814_CR24","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1097\/01.inf.0000188166.17324.60","volume":"24","author":"JS Kahn","year":"2005","unstructured":"Kahn, J. S. & McIntosh, K. History and recent advances in coronavirus discovery. Pediatr. Infect. Dis. J. 24, S223\u2013S227. https:\/\/doi.org\/10.1097\/01.inf.0000188166.17324.60 (2005) (discussion S226).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"3814_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1098\/rstb.2004.1478","volume":"359","author":"EC Holmes","year":"2004","unstructured":"Holmes, E. C. & Rambaut, A. Viral evolution and the emergence of SARS coronavirus. Philos. Trans. R. Soc. B 359, 1059\u20131065. https:\/\/doi.org\/10.1098\/rstb.2004.1478 (2004).","journal-title":"Philos. Trans. R. Soc. B"},{"key":"3814_CR26","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E. & Fouchier, R. A. M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814\u20131820. https:\/\/doi.org\/10.1056\/NEJMoa1211721 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3814_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1126\/science.367.6475.234","volume":"367","author":"J Cohen","year":"2020","unstructured":"Cohen, J. & Normile, D. New SARS-like virus in China triggers alarm. Science 367, 234\u2013235 (2020).","journal-title":"Science"},{"key":"3814_CR28","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/369756a0","volume":"369","author":"EJ Brown","year":"1994","unstructured":"Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756\u2013758. https:\/\/doi.org\/10.1038\/369756a0 (1994).","journal-title":"Nature"},{"key":"3814_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","volume":"78","author":"DM Sabatini","year":"1994","unstructured":"Sabatini, D. M., Erdjumentbromage, H., Lui, M., Tempst, P. & Snyder, S. H. Raft1\u2014A mammalian protein that binds to Fkbp12 in a rapamycin-dependent fashion and is homologous to yeast tors. Cell 78, 35\u201343. https:\/\/doi.org\/10.1016\/0092-8674(94)90570-3 (1994).","journal-title":"Cell"},{"key":"3814_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1074\/jbc.270.2.815","volume":"270","author":"CJ Sabers","year":"1995","unstructured":"Sabers, C. J. et al. Isolation of a protein target of the Fkbp12-rapamycin complex in mammalian-cells. J. Biol. Chem. 270, 815\u2013822. https:\/\/doi.org\/10.1074\/jbc.270.2.815 (1995).","journal-title":"J. Biol. Chem."},{"key":"3814_CR31","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.1199498","volume":"332","author":"PP Hsu","year":"2011","unstructured":"Hsu, P. P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317\u20131322. https:\/\/doi.org\/10.1126\/science.1199498 (2011).","journal-title":"Science"},{"key":"3814_CR32","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1126\/science.1199484","volume":"332","author":"YH Yu","year":"2011","unstructured":"Yu, Y. H. et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322\u20131326. https:\/\/doi.org\/10.1126\/science.1199484 (2011).","journal-title":"Science"},{"key":"3814_CR33","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1038\/onc.2010.139","volume":"29","author":"CA Sparks","year":"2010","unstructured":"Sparks, C. A. & Guertin, D. A. Targeting mTOR: Prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29, 3733\u20133744. https:\/\/doi.org\/10.1038\/onc.2010.139 (2010).","journal-title":"Oncogene"},{"key":"3814_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.tibs.2009.09.004","volume":"34","author":"N Cybulski","year":"2009","unstructured":"Cybulski, N. & Hall, M. N. TOR complex 2: A signaling pathway of its own. Trends Biochem. Sci. 34, 620\u2013627. https:\/\/doi.org\/10.1016\/j.tibs.2009.09.004 (2009).","journal-title":"Trends Biochem. Sci."},{"key":"3814_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi, S. & Munirajan, A. K. Akt in cancer: Mediator and more. Semin. Cancer Biol. 59, 80\u201391. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.002 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"3814_CR36","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","volume":"9","author":"H Hirai","year":"2010","unstructured":"Hirai, H. et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9, 1956\u20131967. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-1012 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"3814_CR37","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science 307, 1098\u20131101. https:\/\/doi.org\/10.1126\/science.1106148 (2005).","journal-title":"Science"},{"key":"3814_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121584","author":"C Magaway","year":"2019","unstructured":"Magaway, C., Kim, E. & Jacinto, E. Targeting mTOR and metabolism in cancer: Lessons and innovations. Cells https:\/\/doi.org\/10.3390\/cells8121584 (2019).","journal-title":"Cells"},{"key":"3814_CR39","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/carcin\/bgy086","volume":"39","author":"A Gkountakos","year":"2018","unstructured":"Gkountakos, A. et al. Unmasking the impact of Rictor in cancer: Novel insights of mTORC2 complex. Carcinogenesis 39, 971\u2013980. https:\/\/doi.org\/10.1093\/carcin\/bgy086 (2018).","journal-title":"Carcinogenesis"},{"key":"3814_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/0008-5472.Can-09-1751","volume":"70","author":"CM Chresta","year":"2010","unstructured":"Chresta, C. M. et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288\u2013298. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-1751 (2010).","journal-title":"Cancer Res."},{"key":"3814_CR41","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.M900301200","volume":"284","author":"CC Thoreen","year":"2009","unstructured":"Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023\u20138032. https:\/\/doi.org\/10.1074\/jbc.M900301200 (2009).","journal-title":"J. Biol. Chem."},{"key":"3814_CR42","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nchembio.117","volume":"4","author":"B Apsel","year":"2008","unstructured":"Apsel, B. et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691\u2013699. https:\/\/doi.org\/10.1038\/nchembio.117 (2008).","journal-title":"Nat. Chem. Biol."},{"key":"3814_CR43","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","volume":"7","author":"ME Feldman","year":"2009","unstructured":"Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38. https:\/\/doi.org\/10.1371\/journal.pbio.1000038 (2009).","journal-title":"PLoS Biol."},{"key":"3814_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.tiv.2016.07.016","volume":"36","author":"DDN de Freitas","year":"2016","unstructured":"de Freitas, D. D. N., Gassen, R. B., Fazolo, T. & Souza, A. P. D. Rapamycin increases RSV RNA levels and survival of RSV-infected dendritic cell depending on T cell contact. Toxicol. In Vitro 36, 114\u2013119. https:\/\/doi.org\/10.1016\/j.tiv.2016.07.016 (2016).","journal-title":"Toxicol. In Vitro"},{"key":"3814_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02193-17","author":"M Li","year":"2018","unstructured":"Li, M. et al. Respiratory syncytial virus replication is promoted by autophagy-mediated inhibition of apoptosis. J. Virol. https:\/\/doi.org\/10.1128\/JVI.02193-17 (2018).","journal-title":"J. Virol."},{"key":"3814_CR46","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.1215135","volume":"335","author":"DW Lamming","year":"2012","unstructured":"Lamming, D. W. et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638\u20131643. https:\/\/doi.org\/10.1126\/science.1215135 (2012).","journal-title":"Science"},{"key":"3814_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol. Cell 22, 159\u2013168. https:\/\/doi.org\/10.1016\/j.molcel.2006.03.029 (2006).","journal-title":"Mol. Cell"},{"key":"3814_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.transproceed.2016.01.002","volume":"48","author":"DQ Zhao","year":"2016","unstructured":"Zhao, D. Q., Li, S. W. & Sun, Q. Q. Sirolimus-based immunosuppressive regimens in renal transplantation: A systemic review. Transplant. Proc. 48, 3\u20139. https:\/\/doi.org\/10.1016\/j.transproceed.2016.01.002 (2016).","journal-title":"Transplant. Proc."},{"key":"3814_CR49","first-page":"8","volume":"1","author":"YK Yakupoglu","year":"2003","unstructured":"Yakupoglu, Y. K. & Kahan, B. D. Sirolimus: A current perspective. Exp. Clin. Transplant. 1, 8\u201318 (2003).","journal-title":"Exp. Clin. Transplant."},{"key":"3814_CR50","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","volume":"67","author":"CG Groth","year":"1999","unstructured":"Groth, C. G. et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67, 1036\u20131042. https:\/\/doi.org\/10.1097\/00007890-199904150-00017 (1999).","journal-title":"Transplantation"},{"key":"3814_CR51","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3892\/ijmm.2013.1494","volume":"32","author":"XC Wang","year":"2013","unstructured":"Wang, X. C. et al. Knockdown of mTOR by lentivirus-mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E-deficient mice. Int. J. Mol. Med. 32, 1215\u20131221. https:\/\/doi.org\/10.3892\/ijmm.2013.1494 (2013).","journal-title":"Int. J. Mol. Med."},{"key":"3814_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","volume":"176","author":"B Levine","year":"2019","unstructured":"Levine, B. & Kroemer, G. Biological functions of autophagy genes: A disease perspective. Cell 176, 11\u201342. https:\/\/doi.org\/10.1016\/j.cell.2018.09.048 (2019).","journal-title":"Cell"},{"key":"3814_CR53","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","volume":"11","author":"DA Guertin","year":"2006","unstructured":"Guertin, D. A. et al. Ablation in mice of the mTORC components Raptor, Rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC alpha but not S6K1. Dev. Cell 11, 859\u2013871. https:\/\/doi.org\/10.1016\/j.devcel.2006.10.007 (2006).","journal-title":"Dev. Cell"},{"key":"3814_CR54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","volume":"127","author":"E Jacinto","year":"2006","unstructured":"Jacinto, E. et al. SIN1\/MIP1 maintains Rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125\u2013137. https:\/\/doi.org\/10.1016\/j.cell.2006.08.033 (2006).","journal-title":"Cell"},{"key":"3814_CR55","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.devcel.2006.08.013","volume":"11","author":"C Shiota","year":"2006","unstructured":"Shiota, C., Woo, J. T., Lindner, J., Shelton, K. D. & Magnuson, M. A. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11, 583\u2013589. https:\/\/doi.org\/10.1016\/j.devcel.2006.08.013 (2006).","journal-title":"Dev. Cell"},{"key":"3814_CR56","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1101\/gad.1461206","volume":"20","author":"Q Yang","year":"2006","unstructured":"Yang, Q., Inoki, K., Ikenoue, T. & Guan, K. L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Gene Dev. 20, 2820\u20132832. https:\/\/doi.org\/10.1101\/gad.1461206 (2006).","journal-title":"Gene Dev."},{"key":"3814_CR57","doi-asserted-by":"publisher","first-page":"U1122","DOI":"10.1038\/ncb1183","volume":"6","author":"E Jacinto","year":"2004","unstructured":"Jacinto, E. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, U1122\u2013U1130. https:\/\/doi.org\/10.1038\/ncb1183 (2004).","journal-title":"Nat. Cell Biol."},{"key":"3814_CR58","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296\u20131302. https:\/\/doi.org\/10.1016\/j.cub.2004.06.054 (2004).","journal-title":"Curr. Biol."},{"key":"3814_CR59","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/ncb2507","volume":"14","author":"XQ Gan","year":"2012","unstructured":"Gan, X. Q. et al. PRR5L degradation promotes mTORC2-mediated PKC-delta phosphorylation and cell migration downstream of G alpha(12). Nat. Cell Biol. 14, 686\u2013696. https:\/\/doi.org\/10.1038\/ncb2507 (2012).","journal-title":"Nat. Cell Biol."},{"key":"3814_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/embr.201338119","volume":"15","author":"X Li","year":"2014","unstructured":"Li, X. & Gao, T. Y. mTORC2 phosphorylates protein kinase C zeta to regulate its stability and activity. Embo Rep. 15, 191\u2013198. https:\/\/doi.org\/10.1002\/embr.201338119 (2014).","journal-title":"Embo Rep."},{"key":"3814_CR61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1083\/jcb.201205030","volume":"201","author":"V Thomanetz","year":"2013","unstructured":"Thomanetz, V. et al. Ablation of the mTORC2 component Rictor in brain or Purkinje cells affects size and neuron morphology. J. Cell Biol. 201, 293\u2013308. https:\/\/doi.org\/10.1083\/jcb.201205030 (2013).","journal-title":"J. Cell Biol."},{"key":"3814_CR62","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1126\/science.369.6501.238","volume":"369","author":"K Kupferschmidt","year":"2020","unstructured":"Kupferschmidt, K. COVID-19 the pandemic virus is slowly mutating. But does it matter?. Science 369, 238\u2013239 (2020).","journal-title":"Science"},{"key":"3814_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2020.100673","author":"AA Dawood","year":"2020","unstructured":"Dawood, A. A. Mutated COVID-19 may foretell a great risk for mankind in the future. New Microb. New Infect. https:\/\/doi.org\/10.1016\/j.nmni.2020.100673 (2020).","journal-title":"New Microb. New Infect."},{"key":"3814_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.013","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell https:\/\/doi.org\/10.1016\/j.cell.2021.03.013 (2021).","journal-title":"Cell"},{"key":"3814_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.572870","author":"C Sarkar","year":"2020","unstructured":"Sarkar, C. et al. Potential therapeutic options for COVID-19: Current status, challenges, and future perspectives. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2020.572870 (2020).","journal-title":"Front. Pharmacol."},{"key":"3814_CR66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5582\/ddt.2020.03035","volume":"14","author":"BH Marouf","year":"2020","unstructured":"Marouf, B. H. & Dizaye, K. Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): Systematic review of clinical studies. Drug Discov. Ther. 14, 109\u2013116. https:\/\/doi.org\/10.5582\/ddt.2020.03035 (2020).","journal-title":"Drug Discov. Ther."},{"key":"3814_CR67","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein, J. et al. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 382, 2327\u20132336. https:\/\/doi.org\/10.1056\/NEJMoa2007016 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3814_CR68","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00221-18","author":"ML Agostini","year":"2018","unstructured":"Agostini, M. L. et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio https:\/\/doi.org\/10.1128\/mBio.00221-18 (2018).","journal-title":"MBio"},{"key":"3814_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","volume":"5","author":"MA Ramakrishnan","year":"2016","unstructured":"Ramakrishnan, M. A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 5, 85\u201386. https:\/\/doi.org\/10.5501\/wjv.v5.i2.85 (2016).","journal-title":"World J. Virol."},{"key":"3814_CR70","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675. https:\/\/doi.org\/10.1038\/nmeth.2089 (2012).","journal-title":"Nat. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03814-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:44:15Z","timestamp":1670075055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03814-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3814"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03814-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-537263\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]},"assertion":[{"value":"18 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24442"}}